Quanterix Corporation - QTRX STOCK NEWS

Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will present virtually at the SVB Leerink Global Healthcare Conference on February 16 at 4:20 PM EST. A live webcast will be accessible via the company's investor relations website, with on-demand replays available for 90 days post-conference. Hrusovsky will also hold virtual one-on-one meetings with institutional investors on February 18. Quanterix focuses on digitizing biomarker analysis to enhance precision health, with applications in oncology, neurology, and more.

Quanterix Corporation (NASDAQ: QTRX) announced its Simoa® technology is advancing neurodegenerative disease research at the UK Dementia Research Institute's Biomarker Factory. Led by Professor Henrik Zetterberg, this initiative aims to enhance early detection of Alzheimer’s and related diseases through ultrasensitive biomarker testing. The UK DRI is collaborating with Quanterix to develop next-generation Simoa technology, which offers a potential 100x improvement in sensitivity. This progress may lead to earlier diagnosis and more effective treatment options for Alzheimer’s.

Quanterix Corporation (NASDAQ: QTRX) announced that its Simoa® technology has played a significant role in a study published in Science, revealing a strong link between the Epstein-Barr virus (EBV) and multiple sclerosis (MS). The study indicates that EBV infection increases MS risk by 32-fold and correlates with elevated levels of neurofilament light (NfL) protein, suggesting EBV's involvement in nerve damage. This research could enhance early detection and treatment of MS, affecting millions globally.

Quanterix Corporation (NASDAQ: QTRX) reported expected Q4 2021 revenue between $29-31 million and full-year revenue between $109-111 million. Noteworthy Q4 growth includes product and service revenue expected at $28-30 million, representing 35% growth year-over-year. For the full year, product revenue is projected at $80-82 million, an 84% increase. The company is advancing precision health with its biomarker detection technology, receiving FDA Breakthrough Device Designation for its Alzheimer’s test.

Quanterix Corporation (NASDAQ: QTRX) announced that its Chairman and CEO, Kevin Hrusovsky, will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022, at 8:15 a.m. EST. This marks Hrusovsky's sixth consecutive year presenting at the conference, where he will discuss the company's growth and vision. Additionally, he will host one-on-one meetings with institutional investors. Investors can access the live webcast of the presentation at Quanterix's conference webpage. The company's technology aims to enhance precision health through advanced biomarker analysis.

Quanterix Corporation (NASDAQ: QTRX) announced advancements in Alzheimer's disease clinical trials utilizing its ultra-sensitive Simoa^® technology. Findings presented at the CTAD conference from November 9-12, 2021, underscored the importance of plasma biomarkers like pTau-181 and pTau-217 in early-stage patient trials, enhancing enrollment efficiency. Biogen and Eli Lilly showcased significant correlations between plasma biomarker reductions and cognitive decline in their studies. Additionally, Simoa's pTau-181 assay received FDA Breakthrough Device Designation, marking a notable achievement for Quanterix.

Quanterix Corporation (NASDAQ: QTRX) will participate in a virtual fireside chat at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Nov. 18 at 8:30 a.m. EST. Executives including CEO Kevin Hrusovsky and CFO Mike Doyle will discuss advancements in biomarker analysis for precision health. A live webcast will be available on their investor relations site, with replays for 90 days post-event. Quanterix's Simoa technology aims to enhance early disease detection and improve patient care across several therapeutic areas.

Quanterix Corporation (NASDAQ: QTRX) reported Q3 2021 total revenue of $27.7M, down 12% year-over-year, primarily due to a prior year one-time license revenue of $11.2M. Non-GAAP total revenue increased 46% to $26.7M. Product revenue surged 77% to $20.7M, driven by a 98% rise in consumables and 44% in instruments. The gross margin decreased to 55.1% from 67.2% due to rising costs. Key advancements included FDA Breakthrough Device designation for the pTau-181 blood test and expanded EUA for the SARS-CoV-2 test. The company aims to enhance precision health diagnostics.